These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 20080644)

  • 1. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.
    Stagg J; Divisekera U; McLaughlin N; Sharkey J; Pommey S; Denoyer D; Dwyer KM; Smyth MJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1547-52. PubMed ID: 20080644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
    Terp MG; Olesen KA; Arnspang EC; Lund RR; Lagerholm BC; Ditzel HJ; Leth-Larsen R
    J Immunol; 2013 Oct; 191(8):4165-73. PubMed ID: 24043904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
    Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy.
    Qiao Z; Li X; Kang N; Yang Y; Chen C; Wu T; Zhao M; Liu Y; Ji X
    Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30823477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
    Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
    Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
    Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
    Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
    Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
    J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD73-deficient mice are resistant to carcinogenesis.
    Stagg J; Beavis PA; Divisekera U; Liu MC; Möller A; Darcy PK; Smyth MJ
    Cancer Res; 2012 May; 72(9):2190-6. PubMed ID: 22396496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD73 therapy impairs tumor angiogenesis.
    Allard B; Turcotte M; Spring K; Pommey S; Royal I; Stagg J
    Int J Cancer; 2014 Mar; 134(6):1466-73. PubMed ID: 23982901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
    Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
    Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.
    Loi S; Pommey S; Haibe-Kains B; Beavis PA; Darcy PK; Smyth MJ; Stagg J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):11091-6. PubMed ID: 23776241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo.
    Salehi Khesht AM; Karpisheh V; Sahami Gilan P; Melnikova LA; Olegovna Zekiy A; Mohammadi M; Hojjat-Farsangi M; Majidi Zolbanin N; Mahmoodpoor A; Hassannia H; Aghebati-Maleki L; Jafari R; Jadidi-Niaragh F
    Int J Biol Macromol; 2021 Sep; 186():849-863. PubMed ID: 34245737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis.
    Koszałka P; Gołuńska M; Stanisławowski M; Urban A; Stasiłojć G; Majewski M; Wierzbicki P; Składanowski AC; Bigda J
    Int J Biochem Cell Biol; 2015 Dec; 69():1-10. PubMed ID: 26545615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
    Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
    Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
    Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
    Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
    Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
    BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression.
    Yegutkin GG; Marttila-Ichihara F; Karikoski M; Niemelä J; Laurila JP; Elima K; Jalkanen S; Salmi M
    Eur J Immunol; 2011 May; 41(5):1231-41. PubMed ID: 21469131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression.
    Sudo H; Tsuji AB; Sugyo A; Kurosawa G; Kurosawa Y; Alexander D; Tsuda H; Saga T; Higashi T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.